Want to see IN:COHANCE full AI Analyst Report?
Top Page
Suven Pharmaceuticals Ltd.
(COHANCE)
Select Model
Select Model
Rating:61Neutral
Price Target:
₹487.00
▼(-45.35% Downside)
Action:Reiterated
Date:09/24/26
The score is driven mainly by solid financial resilience (low leverage and strong revenue growth) but is held back by the sharp deterioration in margins and weaker free-cash-flow conversion. Technicals are moderately constructive with price above key moving averages, while valuation is the largest negative due to the very high P/E.
Positive Factors
Strong Revenue Growth
Rapid FY2026 revenue growth indicates stronger customer activity and expanding commercial demand for the company’s pharmaceutical development and manufacturing services. If sustained, this larger revenue base can support scale benefits, broader customer programs, and future earnings recovery.
Negative Factors
Sharp Margin Compression
The steep decline in gross and net margins shows that higher sales are currently producing a much smaller profit contribution. Persistent margin pressure would weaken earnings quality, reduce reinvestment capacity, and make results more dependent on continued revenue growth rather than efficient execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
Rapid FY2026 revenue growth indicates stronger customer activity and expanding commercial demand for the company’s pharmaceutical development and manufacturing services. If sustained, this larger revenue base can support scale benefits, broader customer programs, and future earnings recovery.
Read all positive factors
Suven Pharmaceuticals Ltd. (COHANCE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹170.05B
Dividend Yield1.68%
Average Volume (3M)61.21K
Price to Earnings (P/E)105.3
Beta (1Y)1.09
Revenue Growth41.24%
EPS Growth-70.51%
CountryIN
Employees1,193
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)4.22
Shares Outstanding382,597,320
10 Day Avg. Volume40,871
30 Day Avg. Volume61,207
Financial Highlights & Ratios
PEG Ratio-1.17
Price to Book (P/B)2.95
Price to Sales (P/S)5.08
P/FCF Ratio85.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹350.00Price Target Upside-60.72% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)5.25
Revenue Forecast (FY)₹23.20B
Suven Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Headquartered in Hyderabad, Cohance Lifesciences Limited operates as a pharmaceutical enterprise, with primary expertise in contract development and manufacturing (CDMO) services. Its business scope also includes the creation of active pharmaceuti...
How the Company Makes Money
Suven Pharmaceuticals Ltd. makes money primarily by providing contract-based development and manufacturing services to external customers in the pharmaceutical industry. Revenue is generated through (1) process research and development work (e.g.,...
Suven Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
84
Very Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 21.41B | 22.69B | 11.98B | 10.51B | 13.40B | 13.20B |
| Gross Profit | 11.44B | 9.11B | 8.22B | 6.80B | 7.52B | 7.46B |
| EBITDA | 3.27B | 4.32B | 4.06B | 4.09B | 5.73B | 5.80B |
| Net Income | 1.06B | 1.79B | 2.68B | 3.00B | 4.11B | 4.54B |
Balance Sheet | ||||||
| Total Assets | 51.92B | 57.30B | 30.32B | 22.54B | 19.66B | 18.30B |
| Cash, Cash Equivalents and Short-Term Investments | 4.59B | 3.26B | 2.90B | 8.21B | 4.84B | 5.26B |
| Total Debt | 2.08B | 4.00B | 2.79B | 649.96M | 703.41M | 971.27M |
| Total Liabilities | 11.96B | 16.96B | 11.91B | 2.03B | 2.31B | 3.02B |
| Stockholders Equity | 38.95B | 39.11B | 16.97B | 20.51B | 17.35B | 15.27B |
Cash Flow | ||||||
| Free Cash Flow | 1.71B | 1.35B | 1.32B | 3.07B | 1.65B | 2.55B |
| Operating Cash Flow | 2.61B | 3.55B | 2.88B | 3.58B | 4.51B | 3.30B |
| Investing Cash Flow | -1.94B | -2.58B | -2.55B | -3.62B | -1.95B | -1.36B |
| Financing Cash Flow | -828.50M | -1.49B | 33.20M | -138.02M | -2.36B | -1.56B |
Suven Pharmaceuticals Ltd. Technical Analysis
Negative
891.10
Price Trends
453.11
Negative
445.66
Negative
410.25
Positive
Market Momentum
4.40
Negative
45.03
Neutral
55.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:COHANCE, the sentiment is Negative. The current price of 891.1 is above the 20-day moving average (MA) of 455.49, above the 50-day MA of 453.11, and above the 200-day MA of 410.25, indicating a neutral trend. The MACD of 4.40 indicates Negative momentum. The RSI at 45.03 is Neutral, neither overbought nor oversold. The STOCH value of 55.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:COHANCE.
Suven Pharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ₹252.76B | 50.78 | ― | 0.17% | 78.33% | 182.61% | |
64 Neutral | ₹208.04B | 31.03 | ― | 0.21% | 24.83% | 36.88% | |
61 Neutral | ₹170.05B | 105.28 | ― | 1.68% | 41.24% | -70.51% | |
60 Neutral | ₹1.29T | 96.96 | ― | 0.08% | 23.03% | 95.69% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | ₹147.29B | 41.54 | ― | 0.54% | 16.27% | -23.50% | |
51 Neutral | ₹30.43B | 81.94 | ― | 0.45% | 27.30% | 456.80% |
* General Sector Average
IN:COHANCE
Suven Pharmaceuticals Ltd.
444.45
-298.60
-40.19%
IN:GRANULES
Granules India Limited
839.55
267.34
46.72%
IN:JUBLPHARMA
Jubilant Pharmova Limited
924.70
-238.38
-20.50%
IN:LAURUSLABS
Laurus Labs Ltd.
2,392.00
1,417.82
145.54%
IN:NEULANDLAB
Neuland Laboratories Ltd.
19,701.10
2,581.84
15.08%
IN:SOLARA
Solara Active Pharma Sciences Ltd.
633.05
1.10
0.17%
Suven Pharmaceuticals Ltd. Corporate Events
Cohance Lifesciences Completes USFDA Inspection at Shamshabad Plant
Sep 4, 2026
Cohance Lifesciences Limited has reported the completion of a United States Food and Drug Administration inspection at its Shamshabad, Telangana formulation plant, conducted between August 27 and September 4, 2026. The audit ended with Form FDA 48...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.